<DOC>
	<DOCNO>NCT00259870</DOCNO>
	<brief_summary>This two part study design evaluate safety efficacy SB-773812 treatment acute schizophrenia . Subjects acute schizophrenia randomize adaptive design study receive placebo , SB-773812 60mg olanzapine 15mg 12 week Part A . An interim analysis conduct assess efficacy safety SB-773812 60mg dose compare placebo . Based data , two dos SB-773812 add randomization Part B .</brief_summary>
	<brief_title>SB-773812 Administered In Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Meets diagnostic criterion schizophrenia define DSMIV . PANSS total score least 70 Screen Baseline minimum score 4 ( moderate ) least 2 follow : conceptual disorganization ( P2 ) hallucinatory behaviour ( P3 ) suspiciousness ( P6 ) unusual think content ( G9 ) Screen Baseline visit Subjects history epilepsy seizure disorder , first episode schizophrenia psychotic disorder ( e.g . residual type schizophrenia , schizophreniform disorder , schizoaffective disorder , delusional disorder , etc . ) Bipolar disorder , history substance dependence , medical psychiatric disorder would interfere accurate assessment safety efficacy eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>PANSS</keyword>
	<keyword>Acute</keyword>
	<keyword>Cognition</keyword>
</DOC>